Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Free Cash Flow (2018 - 2025)

TELA Bio (TELA) has 8 years of Free Cash Flow data on record, last reported at -$6.0 million in Q3 2025.

  • For Q3 2025, Free Cash Flow rose 33.54% year-over-year to -$6.0 million; the TTM value through Sep 2025 reached -$32.1 million, up 29.55%, while the annual FY2024 figure was -$42.6 million, 2.69% down from the prior year.
  • Free Cash Flow reached -$6.0 million in Q3 2025 per TELA's latest filing, up from -$7.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$5.7 million in Q2 2021 and bottomed at -$14.7 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$9.5 million, with a median of -$9.8 million recorded in 2025.
  • Peak YoY movement for Free Cash Flow: tumbled 115.88% in 2022, then soared 33.57% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$10.1 million in 2021, then fell by 8.54% to -$11.0 million in 2022, then dropped by 2.49% to -$11.3 million in 2023, then rose by 25.86% to -$8.3 million in 2024, then rose by 27.5% to -$6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$6.0 million in Q3 2025, -$7.9 million in Q2 2025, and -$9.8 million in Q1 2025.